A Trial of Aclaris Therapeutics, Inc. (ATI)-450 in Patients With Moderate-severe Novel Coronavirus Disease 2019 (COVID-19)
Status:
Completed
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
COVID-19 morbidity and mortality has been associated with Cytokine Release Syndrome (CRS) and
Acute Respiratory Distress Syndrome (ARDS).
ATI-450 is an oral small molecule MAPKAPK2 (MK2) inhibitor that potently inhibits multiple
inflammatory cytokines.
The investigator hypothesizes that MK2 pathway blockade during active COVID-19 infection in
hospitalized participants will result in improvement in respiratory-failure free survival.